Next-generation antibody drug for immuno-oncology treatment: anti-TIM3 antibody development

Unprecedented advances have been made in the treatment of cancer through the use of antibody against immune checkpoints, priming immune system instead of targeting cancer, with approval of several antibodies for multiple cancer types. However, so far we are merely seeing the tip of the iceberg because responses to this form of therapy are not universal. Next-generation antibody drug is needed. TIM-3 negatively regulates immune system and is one of the next generation targets. We have generated 13 clones of TIM-3 antibodies, potentially can be anti-tumor drug. Here, a serial of experiments in biochemical, cellular, and animal models experiments are proposed. Evolution of this understanding will ultimately help guide treatment strategies to enhance therapeutic responses.

Faculty Supervisor:

Yuzhuo Wang

Student:

Charlene Hoi-Broad

Partner:

Applied Biological Materials

Discipline:

Medicine

Sector:

Medical devices

University:

University of British Columbia